ArticleCurrent microbiology2024
Characterization of a Putative Lysin from Enterococcus faecalis Phage IME-EFm1 and Determination of its Protective Efficacy in Mice.
Article in Current microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of an IMSA assay targeting the hly gene for detection of Listeria monocytogenes in food samples.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The rising tide of bacterial drug resistance has sparked renewed interest in bacteriophages, the natural predators of bacteria. Our study highlights IME-EFm1, a Caudoviricetes bacteriophage specifically targeting Enterococcus faecium. Through our investigations, we identified that the gene IME-EFm1-ORF24 encodes an amidase, referred to as gp24, with promising lytic capabilities. Remarkably, gp24 exhibited a wider lytic spectrum than its parent phage, successfully lysing 26 out of 32 E. faecium strains, compared to the phage's ability to lyse only 21. This protein demonstrated robust antibacterial activity, remaining effective at temperatures between 25 °C and 60 °C and across a pH range of 6 to 12. Additionally, gp24 displayed significant anti-biofilm properties, effectively dismantling established biofilms in vitro. In a mouse model of abdominal infection, gp24 achieved a 75% protection rate against a dose of 2 × 10
Indexed as
Identifiers
39623033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.